Alnylam Pharmaceuticals, Inc. (ALNY) — Fair Value Analysis

Base-case fair value (P50): $346.86 · Current price: $298.76 · Verdict: Undervalued

Alnylam Pharmaceuticals Inc (ALNY) is currently assessed as Fairly Valued based on our proprietary Monte Carlo simulations. With ALNY trading at $298.76, our median fair value (P50) stands at $346.86, suggesting a potential +16.1% upside. This indicates that while the stock isn't significantly undervalued, there remains a modest upward trajectory to its probabilistic fair value.

The Verdict on ALNY

Our Monte Carlo analysis assigns Alnylam Pharmaceuticals Inc (ALNY) a Fairly Valued verdict. The current market price of $298.76 sits reasonably close to our median fair value estimate of $346.86. This narrow gap, reflecting a +16.1% difference, aligns with a company recognized for its strong operational and financial health. While some investors might seek more pronounced mispricing, ALNY's position suggests its current valuation largely reflects its fundamental strength and future prospects without being excessively stretched.

How ALNY stacks up against peers

Despite the 'n/a' sector classification, ALNY's strong quality tier is a key differentiator when considering its market position. This robust health suggests ALNY outperforms many peers in terms of operational and financial metrics, even if direct sector comparisons are broad. The current price of $298.76 relative to our $346.86 fair value suggests the market has largely priced in ALNY's inherent strengths, limiting dramatic undervaluation often seen in less sound companies. Investors should interpret the +16.1% not as a sign of deep distress, but rather as recognition of ongoing, steady value creation.

What this means for investors

For investors, the Fairly Valued assessment of ALNY, coupled with its strong quality tier, implies a profile of stability rather than speculative arbitrage. While the +16.1% offers a modest target, the Monte Carlo simulations suggest a balanced risk-reward at the current $298.76 relative to $346.86. This doesn't rule out more significant upside scenarios in a bull case, nor does it discount downside risks, but these probabilities are tighter for companies of ALNY's caliber. For a comprehensive understanding of ALNY's full fair value distribution, including bear and bull case scenarios, and to track its evolving fair value, sign up for a free FairCurve account.